239 related articles for article (PubMed ID: 10942056)
1. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
Haioun C; Besson C; Lepage E; Thieblemont C; Simon D; Rose C; Tilly H; Sonet A; Lederlin P; Attal M; Brière J; Reyes F
Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
[TBL] [Abstract][Full Text] [Related]
5. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
Mounier N; Morel P; Haioun C; Coiffier B; Tilly H; Chatelain C; Lederlin P; Thyss A; Herbrecht R; Gisselbrecht C; Lepage E
Cancer; 1998 May; 82(10):1952-62. PubMed ID: 9587130
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
7. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
8. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Orellana-Noia VM; Reed DR; McCook AA; Sen JM; Barlow CM; Malecek MK; Watkins M; Kahl BS; Spinner MA; Advani R; Voorhees TJ; Snow A; Grover NS; Ayers A; Romancik J; Liu Y; Huntington SF; Chavez JC; Saeed H; Lazaryan A; Raghunathan V; Spurgeon SE; Ollila TA; Del Prete C; Olszewski A; Ayers EC; Landsburg DJ; Echalier B; Lee J; Kamdar M; Caimi PF; Fu T; Liu J; David KA; Alharthy H; Law J; Karmali R; Shah H; Stephens DM; Major A; Rojek AE; Smith SM; Yellala A; Kallam A; Nakhoda S; Khan N; Sohail MA; Hill BT; Barrett-Campbell O; Lansigan F; Switchenko J; Cohen J; Portell CA
Blood; 2022 Jan; 139(3):413-423. PubMed ID: 34570876
[TBL] [Abstract][Full Text] [Related]
9. Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
Santambrogio E; Nicolosi M; Vassallo F; Castellino A; Novo M; Chiappella A; Vitolo U
Expert Rev Hematol; 2019 Sep; 12(9):787-796. PubMed ID: 31305170
[No Abstract] [Full Text] [Related]
10. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
[TBL] [Abstract][Full Text] [Related]
11. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
Moe PJ; Holen A; Nygaard R; Glomstein A; Madsen B; Hellebostad M; Stokland T; Wefring KW; Steen-Johnsen J; Nielsen B; Hapnes C; Børsting S
Pediatr Hematol Oncol; 2003; 20(3):187-200. PubMed ID: 12637215
[TBL] [Abstract][Full Text] [Related]
13. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
14. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.
Bos GM; van Putten WL; van der Holt B; van den Bent M; Verdonck LF; Hagenbeek A
Ann Oncol; 1998 Feb; 9(2):191-4. PubMed ID: 9553665
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
[TBL] [Abstract][Full Text] [Related]
16. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma.
Garwood MJ; Hawkes EA; Churilov L; Chong G
Cancer Chemother Pharmacol; 2020 Jan; 85(1):133-140. PubMed ID: 31848681
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.
Hall KH; Valla K; Flowers CR; Cohen JB
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):89-94. PubMed ID: 30528416
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Haioun C; Lepage E; Gisselbrecht C; Salles G; Coiffier B; Brice P; Bosly A; Morel P; Nouvel C; Tilly H; Lederlin P; Sebban C; Brière J; Gaulard P; Reyes F
J Clin Oncol; 2000 Aug; 18(16):3025-30. PubMed ID: 10944137
[TBL] [Abstract][Full Text] [Related]
20. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]